Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
Sangamo has always been a dog. It's been around TWO DECADES and has changed targets a bunch. Sangamo is one of these companies that continues to miss deadlines, fail in trials, yet somehow doesnt go to bagel-town, and 5-10 years later reinvents itself, only to fail again. Geron is another. Novavax another. NKTR is likely going to be on that list. Sangamo was big on peripheral neuropathy for awhile. then onto HIV. then regenerative medicine (I think?) ... poor focus, poor execution, long history of failures.

There are some companies that fade into the background for long enough that the last wave of biotech newbies who got burned have abandoned biotech, only to feast on the next round of newbies.

It's an art, really.

Rulebook #10. If a company has changed therapeutic focus more than twice and doesnt have a marketed drug and has been public more than 5 years, run.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.